NCT04644952 The Rise in Robotic Atypical Segmentectomies
| NCT ID | NCT04644952 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Lung Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2020-09-15 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2020-09-15 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the increased rate of robotic atypical segmentectomies. Segmentectomy refers to removing a section of a lobe of the lung. Reviewing patients' data retrospectively may help researchers determine whether robotic surgery has led to an increase in atypical segmentectomy.
Eligibility Criteria
Inclusion Criteria: * Patients who underwent a lung resection from 2004 to 2019
Contact & Investigator
David C Rice
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT04644952 clinical trial?
This trial is open to participants of all sexes, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04644952 currently recruiting?
Yes, NCT04644952 is actively recruiting participants. Contact the research team at drice@mdanderson.org for enrollment information.
Where is the NCT04644952 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT04644952 clinical trial?
NCT04644952 is sponsored by M.D. Anderson Cancer Center. The principal investigator is David C Rice at M.D. Anderson Cancer Center. The trial plans to enroll 600 participants.